CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
Yeteng MuXingang GuanPublished in: Current medicinal chemistry (2024)
Immune checkpoint inhibitors (ICIs) have shown unprecedented efficacy in treating many advanced cancers. Although FDA-approved ICIs have shown promising efficacy in treating many advanced cancers, their application is greatly limited by the low response rate, immune-related adverse events (irAE), and drug resistance. Developing novel ICIs holds great promise to improve the survival and prognosis of advanced cancer patients. T-Cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on T cells, natural killer (NK) cells, and T regulatory cells. Increasing reports have shown that the disrupting CD155-TIGIT axis could activate the immune system and restore antitumor immune response. This review briefly summarized the role of TIGIT in tumor immune escape and targeting CD155-TIGIT axis drugs in preclinical and clinical trials for cancer immunotherapy.
Keyphrases
- nk cells
- clinical trial
- immune response
- induced apoptosis
- transcription factor
- stem cells
- randomized controlled trial
- dendritic cells
- cell death
- signaling pathway
- inflammatory response
- young adults
- mesenchymal stem cells
- toll like receptor
- childhood cancer
- free survival
- open label
- binding protein
- phase ii
- double blind